News & Updates

In men with prostate cancer and concomitant atherosclerotic cardiovascular disease (ASCVD), major adverse cardiovascular event (MACE) incidence did not differ between those who were treated with degarelix or leuprolide, according to findings of the PRONOUNCE trial.

In individuals with type 2 diabetes (T2D), the glucagon-like peptide-1 receptor agonist (GLP1-RA) liraglutide appeared to yield a cardioprotective benefit, data from the secondary endpoint analysis of the LIRAFLAME* trial suggests.

Women on menopausal hormone therapy are at risk of developing hypertension, particularly those using oral oestrogen plus a progestogen such as pregnane and norpregnane derivatives, according to a study.

Among women receiving immunosuppression treatment with mammalian target of rapamycin inhibitors (mTORi), the incidence of ovarian cyst appears to be a common adverse event, according to the results of a systematic review and meta-analysis.

Extending treatment with letrozole for 5 years improves disease-free survival (DFS) rates in postmenopausal women with early-stage breast cancer who have already received tamoxifen for 2–3 years, according to the GIM4* trial.

Treatment with delgocitinib ointment, a topical Janus kinase (JAK) inhibitor, for paediatric atopic dermatitis (AD) is effective and well tolerated when applied for up to 56 weeks, according to a phase III trial and a subsequent open-label, long-term study in Japan.

Oteseconazole (VT-1161), a novel investigational fungal CYP51 inhibitor, outdid fluconazole/placebo for managing acute and recurrent* vulvovaginal candidiasis (VVC), according to data from the phase III ultraVIOLET trial.

Intravenous dosing regimens of vedolizumab appear to favourably alter outcomes in patients with fistulizing Crohn’s disease, according to data from the phase IV ENTERPRISE trial.

A large international database study has shown that children and adolescents with cancer have an elevated risk of severe or critical disease if infected with COVID-19. Furthermore, about half the patients receiving cancer therapy experienced modifications to their treatment regimens.